The US Food and Drug Administration on Friday approved NPS Pharmaceuticals’ (Nasdaq: NPSP) Natpara (parathyroid hormone) to control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism, a rare disease that affects about 60,000 people in the USA.
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH. Natpara, a bioengineered replica of human PTH, is expected to be available in the second quarter of 2015, said NPS Pharma.
NPS Pharma is the subject of a $5.2 billion ($46.00 per share) agreed takeover by Ireland-headquartered drugmaker Shire’s (LSE: SHP), and the approval of Natpara is seen as validation of the 50% premium that Shire has offered for the company. NPS Pharma’s shares edged up 0.68% to $45.95 in after-hours trading on January 23. Shire’s shares gained 2.2% to £48.16.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze